Literature DB >> 19383442

CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.

H Tumani1, V Lehmensiek, D Rau, I Guttmann, G Tauscher, H Mogel, C Palm, V Hirt, S D Suessmuth, I Sapunova-Meier, A C Ludolph, J Brettschneider.   

Abstract

Cerebrospinal fluid (CSF) is a promising source of biomarkers in clinically isolated syndrome (CIS), which frequently presents as a first episode of multiple sclerosis (MS). Using the two-dimensional difference in gel electrophoresis (2-D DIGE), we compared CSF samples from patients with CIS that remained CIS (CIS-CIS, n=8) over a follow-up time of 2 years and from patients with CIS that developed definite MS of the relapsing-remitting subtype (CIS-RRMS, n=8) over the same period. Protein spots that showed significant differences between patients and controls were selected for further analysis by MALDI-TOF mass spectrometry. For validation of identified spots ELISA experiments were performed. We identified one protein that was upregulated in CIS-RRMS (serin peptidase inhibitor) and eight proteins (alpha-1-B-glycoprotein, Fetuin-A, apolipoprotein A4, haptoglobin, human Zinc-alpha-2-glycoprotein (ZAG), Retinol-binding protein, superoxid dismutase 1, transferrin) that were down-regulated in CIS-RRMS vs. CIS-CIS. For Fetuin-A, our findings could be confirmed by ELISA. The pathophysiological role as well as clinical relevance of these candidate proteins in CIS remains to be further clarified by future studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383442     DOI: 10.1016/j.neulet.2009.01.057

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

Review 1.  The emerging role of vitamin D binding protein in multiple sclerosis.

Authors:  Giulio Disanto; Sreeram V Ramagopalan; Andrea E Para; Lahiru Handunnetthi
Journal:  J Neurol       Date:  2010-11-02       Impact factor: 4.849

Review 2.  Correlation of geographic distributions of haptoglobin alleles with prevalence of multiple sclerosis (MS) - a narrative literature review.

Authors:  Vladimir V Bamm; Arielle M Geist; George Harauz
Journal:  Metab Brain Dis       Date:  2016-11-02       Impact factor: 3.584

3.  Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.

Authors:  Kaushal S Gandhi; Fiona C McKay; Eve Diefenbach; Ben Crossett; Stephen D Schibeci; Robert N Heard; Graeme J Stewart; David R Booth; Jonathan W Arthur
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

4.  Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis.

Authors:  Marcel P Stoop; Vaibhav Singh; Lennard J Dekker; Mark K Titulaer; Christoph Stingl; Peter C Burgers; Peter A E Sillevis Smitt; Rogier Q Hintzen; Theo M Luider
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

5.  Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis.

Authors:  Laura F Dagley; Nathan P Croft; Ruth Isserlin; Jonathan B Olsen; Vincent Fong; Andrew Emili; Anthony W Purcell
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

6.  The Newest Hypothesis about Vitiligo: Most of the Suggested Pathogeneses of Vitiligo Can Be Attributed to Lack of One Factor, Zinc-α2-Glycoprotein.

Authors:  Nooshin Bagherani
Journal:  ISRN Dermatol       Date:  2012-06-19

7.  Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.

Authors:  Annelies Vanheel; Ruth Daniels; Stéphane Plaisance; Kurt Baeten; Jerome J A Hendriks; Pierre Leprince; Debora Dumont; Johan Robben; Bert Brône; Piet Stinissen; Jean-Paul Noben; Niels Hellings
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

8.  Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis.

Authors:  Simona Perga; Alessandra Giuliano Albo; Katarzyna Lis; Nicoletta Minari; Sara Falvo; Fabiana Marnetto; Marzia Caldano; Raffaella Reviglione; Paola Berchialla; Marco A Capobianco; Maria Malentacchi; Davide Corpillo; Antonio Bertolotto
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

9.  Gray matter is targeted in first-attack multiple sclerosis.

Authors:  Steven E Schutzer; Thomas E Angel; Tao Liu; Athena A Schepmoes; Fang Xie; Jonas Bergquist; László Vécsei; Denes Zadori; David G Camp; Bart K Holland; Richard D Smith; Patricia K Coyle
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

Review 10.  Biomarkers of therapeutic response in multiple sclerosis: current status.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.